SalaryGuide
AboutPricingFor Employers

Marketing jobs

5 marketing jobs

MannKind Corporation logo
2 weeks ago

Director, Marketing

MannKind Corporation

Westlake Village, CA (On-site)Full time$184K/yr – $276K/yr
MannKind Corporation logo
2 weeks ago

Director, Marketing

MannKind Corporation

Westlake Village, CA (Unknown)$184K/yr – $276K/yr
MannKind Corporation logo
3 months ago

Vice President, Marketing

MannKind Corporation

Westlake Village, CA (On-site)Full time$264K/yr – $396K/yr
MannKind Corporation logo
4 months ago

Marketing Intern- FUROSCIX

MannKind Corporation

Burlington, MA (Hybrid)Full time
MannKind Corporation logo
4 months ago

Marketing Intern- FUROSCIX

MannKind Corporation

Burlington, MA (Hybrid)Internship

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

5 jobs
MannKind Corporation logo

Director, Marketing

MannKind Corporation

Westlake Village, CA (On-site)

$184K/yr - $276K/yrIn-houseFull-timeDirector/executive15+ years exp.
2 weeks ago
MannKind Corporation logo

Director, Marketing

MannKind Corporation

Westlake Village, CA (Unknown)

$184K/yr - $276K/yrIn-houseDirector/executive15+ years exp.
2 weeks ago
MannKind Corporation logo

Vice President, Marketing

MannKind Corporation

Westlake Village, CA (On-site)

$264K/yr - $396K/yrIn-houseFull-timeDirector/executive15+ years exp.
3 months ago
MannKind Corporation logo

Marketing Intern- FUROSCIX

MannKind Corporation

Burlington, MA (Hybrid)

In-houseFull-timeIntern/new grad
4 months ago
MannKind Corporation logo

Marketing Intern- FUROSCIX

MannKind Corporation

Burlington, MA (Hybrid)

In-houseInternshipIntern/new grad
4 months ago
MannKind Corporation logo
MannKind Corporation

Director, Marketing

Westlake Village, CA (On-site)

$184K/yr – $276K/yrDirector/Executive15+ years expFull time

Posted 2 weeks ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own marketing leadership for a pharma/healthcare portfolio with strong cross-functional ownership across brand, KOL engagement, and market research to inform product positioning and multi-channel plans.

  • Brand and cross-functional ownership: drive brand messaging, launches, and alignment with field sales, regulatory, R&D, and medical affairs.
  • KOL and patient engagement: build initiatives with HCPs, patient groups, and medical societies to influence adoption and advocacy.
  • Market insights and performance: run market research, track KPIs, and optimize programs across digital and traditional channels.

Job Description

Responsibilities

  • Brand Management: Build and maintain a strong brand presence. Execute brand strategies, agency management, manage brand messaging, and ensure consistent brand communication across different channels and touchpoints.
  • Execute marketing plans: Execute comprehensive marketing initiatives to all customer groups (HCP, allied health and consumer). Set clear goals, identifying target segments, positioning products effectively, and creating plans to drive product adoption and revenue growth. Manage all multi-channel marketing programs including app development and devices.
  • Cross-functional Collaboration: Partner closely with various departments, such as field sales management, regulatory affairs, R&D, and medical affairs. Strong collaboration, align efforts, gather input, and drive cross-functional initiatives to ensure successful product launches and marketing campaigns. Leads marketing activities for Product Review Committee.
  • Customer/ KOL Engagement: Develop initiatives with key opinion leaders, healthcare professionals, and patient advocacy groups, and medical societies.
  • Market Research and Analysis: Execute market research plan, gather customer insights, and analyze market data. This includes monitoring industry trends, identifying market opportunities, and leveraging market research findings to inform product positioning and marketing strategies.
  • Marketing communications: Oversee the development of compelling marketing collateral, digital content, sales tools, and advertising campaigns to effectively reach target audiences and support sales efforts. Effectively convey complex scientific and medical information to various audiences, including healthcare professionals, patients, and internal stakeholders.
  • Performance tracking and reporting: Establish key performance indicators (KPIs) to measure the effectiveness of HCP marketing initiatives. Conduct regular engagement with field force and collect feedback to incorporate suggestions as appropriate. Regularly track, analyze, and report on marketing activities, providing insights and recommendations for optimization.
  • Observe all Company, Health, Safety, Compliance and Environmental guidelines.
  • Duties and responsibilities are not limited to the work listed above and may include other assignments, as necessary.

Requirements

  • Bachelor's degree in Marketing, Business Administration, or a related field. MBA preferred.
  • Proven track record of at least 15 years in the pharmaceutical or healthcare industry with at least 10 years marketing experience.
  • Experience launching product(s) in the diabetes category is preferred.
  • Extensive experience in HCP marketing in the pharmaceutical/medical device/biotech industry required.
  • Experience in developing and executing cost-effective social and digital marketing strategies.
  • Previous experience in the diabetes marketplace, with emphasis in insulin therapy is preferred.
  • Record of increasing responsibility within sales and marketing.
  • Demonstrated analytical skills and the ability to think strategically and solve problems.
  • Focused on team culture through collaboration and working cross-functionally to drive business results in a lean, fast-paced environment.

Preferred

  • Experience launching product(s) in the diabetes category is preferred.
  • Previous experience in the diabetes marketplace, with emphasis in insulin therapy is preferred.
MannKind Corporation logo

MannKind Corporation

3.6 Glassdoor

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.Please visit mannkindcorp.com to learn more.

Founded in 1991
Danbury, Connecticut, USA
803 employees (22 in marketing)
www.mannkindcorp.com
79% recommend to a friend
85% CEO approval

Traffic Signals

Monthly Visitors
14.4K
Traffic Source Mix
Search
45%
Direct
40.4%
Referral
7.5%
Social
5.6%
Paid
1.4%

Headcount Trend

Current headcount: ~803

Marketing Team

Marketing Team Size
12 (1% of company)
Median Career Experience
21.5 years
Median Tenure
1.8 years
Marketing Roles Posted (Last 30 Days)
1

People

Founders / CEO

Michael Castagna
Michael Castagna
Chief Executive Officer
At the company for 10 years 5 months

HR / Recruitment

Andrew Garrison
Andrew Garrison
Senior Associate Manager, Talent Acquisition
At the company for 3 years 5 months
Karen Marnell
Karen Marnell
Senior Talent Acquisition Specialist
At the company for 5 years 1 month

Marketing Leadership

Tara Hendrzak
Tara Hendrzak
VP of Marketing
At the company for 7 months
Stuart Tross
Stuart Tross
Chief People & Workplace Officer & EVP (Responsible for HR, Internal Comms & Office Facilities)
At the company for 9 years 8 months
Joan Rogers
Joan Rogers
Head of Marketing, Endocrine Business Unit
At the company for 2 years 9 months
Mary Rowell
Mary Rowell
Associate Director, Patient Marketing
At the company for 9 months

Funding

Total Funding
$475M
Last Raise
$75M
Post IPO Debt, 7 months ago

Funding History

  • Aug 2025
    Post IPO Debt • $75M
  • Mar 2021
    Post IPO Debt • $200M
  • Dec 2018
    Post IPO Equity • $40M

Recent News

MannKind Corporation (NASDAQ:MNKD) Given Average Recommendation of "Moderate Buy" by Brokerages
Nov 21, 2025 • MarketBeat
Is MannKind Corporation (NNFN) stock attractive post correction - 2025 Market WrapUp & Accurate Buy Signal Alerts
Nov 21, 2025 • newser.com
What momentum indicators show for MannKind Corporation stock - Wall Street Watch & Expert Curated Trade Ideas
Nov 19, 2025 • newser.com
What momentum indicators show for MannKind Corporation stock - July 2025 Institutional & Verified Swing Trading Watchlist
Nov 19, 2025 • newser.com
Can swing trading help recover from MannKind Corporation losses
Nov 16, 2025 • newser.com
Is MannKind Corporation stock attractive for retirement portfolios - Market Risk Analysis & Risk Controlled Swing Alerts
Nov 16, 2025 • newser.com
Connor Clark & Lunn Investment Management Ltd. Decreases Position in MannKind Corporation $MNKD
Nov 15, 2025 • MarketBeat
How MannKind Corporation stock responds to policy changes - Portfolio Return Summary & Long-Term Capital Growth Ideas
Nov 14, 2025 • newser.com
Los Angeles Capital Management LLC Buys 177,440 Shares of MannKind Corporation $MNKD
Nov 12, 2025 • MarketBeat
MannKind to Present at the Jefferies Global Healthcare Conference
Nov 11, 2025 • Yahoo Finance
MannKind Corp (MNKD) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic Expansions ...
Nov 8, 2025 • Yahoo Finance
Revenue Jump and Portfolio Expansion Could Be a Game Changer for MannKind (MNKD)
Nov 7, 2025 • Sahm
MANNKIND CORP SEC 10-Q Report
Nov 5, 2025 • TradingView
MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say
Nov 5, 2025 • Yahoo Finance
Simon Quick Advisors LLC Acquires Shares of 48,216 MannKind Corporation $MNKD
Nov 5, 2025 • MarketBeat
MannKind Corporation (NASDAQ:MNKD) Short Interest Up 37.4% in October
Nov 4, 2025 • MarketBeat
MannKind Corp (MNKD) Q3 2025 Earnings Report Preview: What to Expect
Nov 4, 2025 • Yahoo Finance
MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025
Oct 29, 2025 • Yahoo Finance
MannKind Corporation to Announce Q3 2025 Financial Results and Host Webcast on November 5, 2025
Oct 29, 2025 • Quiver Quantitative
MannKind Corporation (NASDAQ:MNKD) Receives Average Recommendation of "Moderate Buy" from Brokerages
Oct 27, 2025 • MarketBeat
How analysts rate MannKind Corporation stock today - July 2025 Recap & Safe Capital Growth Stock Tips
Oct 23, 2025 • newser.com
How MannKind Corporation stock responds to policy changes - Weekly Trend Summary & Comprehensive Market Scan Insights
Oct 23, 2025 • newser.com
How MannKind Corporation stock responds to policy changes - Market Activity Report & Consistent Profit Trading Strategies
Oct 21, 2025 • newser.com
Is MannKind Corporation (NNFN) stock attractive post correction - 2025 Pullback Review & Weekly Return Optimization Alerts
Oct 20, 2025 • nchmf.gov.vn
Is MannKind Corporation (NNFN) stock attractive post correction - Profit Target & Verified Stock Trade Ideas
Oct 20, 2025 • newser.com
Earnings Beat: Is MannKind Corporation stock vulnerable to regulatory risks - Market Growth Summary & Reliable Price Action Trade Plans
Oct 18, 2025 • nchmf.gov.vn
Will MannKind Corporation stock remain a Wall Street favorite - 2025 Buyback Activity & AI Forecast Swing Trade Picks
Oct 17, 2025 • nchmf.gov.vn
Portfolio Shifts: Will MannKind Corporation stock remain a Wall Street favorite - Market Activity Report & Technical Buy Zone Confirmation
Oct 17, 2025 • nchmf.gov.vn
MannKind: Durable Cash Engine, Optional Catalysts Pending (NASDAQ:MNKD)
Oct 15, 2025 • Seeking Alpha
MannKind (MNKD) Is Down 9.9% After FDA Reviews Afrezza for Pediatric Use Will Growth Prospects Shift?
Oct 14, 2025 • Sahm
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes
Oct 13, 2025 • Yahoo Finance
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes
Oct 13, 2025 • GlobeNewswire
MannKind Corporation Submits Supplemental Biologics License Application for Needle-Free Afrezza Inhalation Powder for Pediatric Diabetes Treatment
Oct 13, 2025 • Quiver Quantitative
MannKind completes acquisition of scPharmaceuticals in $296.5 million deal
Oct 9, 2025 • investing.com
MannKind Corporation Completes Acquisition of scPharmaceuticals Inc. to Enhance Growth in Cardiometabolic Care
Oct 7, 2025 • Quiver Quantitative
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
Oct 7, 2025 • Yahoo Finance
Over $370M Annualized Run Rate — MannKind Completes Acquisition of scPharmaceuticals; $5.35 Cash
Oct 7, 2025 • Stock Titan
MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer
Sep 29, 2025 • GlobeNewswire
MNKD: HC Wainwright & Co. Reiterates Buy Rating with $11 Target | MNKD Stock News
Sep 18, 2025 • GuruFocus
H.C. Wainwright Reiterates a Buy Rating on MannKind Corporation (MNKD)
Aug 30, 2025 • Yahoo Finance
MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy
Aug 27, 2025 • GlobeNewswire
Latham & Watkins Advises scPharmaceuticals in Acquisition by MannKind Corporation
Aug 27, 2025 • Latham & Watkins LLP
Leerink Partners Reiterates a Buy Rating on MannKind Corporation (MNKD), Keeps the PT at $7
Aug 25, 2025 • Insider Monkey
Leerink Partners Reiterates a Buy Rating on MannKind Corporation (MNKD), Keeps the PT at $7
Aug 25, 2025 • Yahoo Finance
MannKind Corporation to Acquire scPharmaceuticals: More Details Inside
Aug 25, 2025 • Stocktwits
Leerink Partners Reiterates a Buy on MannKind Corporation (MNKD), Keeps the PT
Aug 22, 2025 • Yahoo Finance
MannKind (MNKD) Secures $500M Financing to Advance Inhaled Therapies Pipeline
Aug 17, 2025 • Yahoo Finance
MannKind Corporation (NASDAQ:MNKD) Q2 2025 Earnings Call Transcript
Aug 7, 2025 • Insider Monkey
MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement
Aug 7, 2025 • WebWire
MannKind And Blackstone Announce Up To $500 Mln Strategic Financing Agreement
Aug 6, 2025 • Nasdaq
MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update
Aug 6, 2025 • GlobeNewswire
MannKind Corporation Reports Second Quarter 2025 Financial Resu
Aug 6, 2025 • GuruFocus
MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement
Aug 6, 2025 • MannKind
MannKind selloff on earnings overdone, says H.C. Wainwright
Aug 6, 2025 • thefly.com
MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update
Aug 6, 2025 • BioSpace
MannKind, Blackstone enter up to $500M strategic financing agreement
Aug 6, 2025 • thefly.com
MannKind reports Q2 non-GAAP EPS 5c, consensus 8c
Aug 6, 2025 • thefly.com
MannKind Corporation announced that it expects to receive $200 million in funding from Blackstone Alternative Credit Advisors LP
Aug 6, 2025 • MarketScreener
MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement
Aug 6, 2025 • BioSpace
MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025
Jul 30, 2025 • MannKind
MannKind Corporation (MNKD) Presented Inhaled Insulin Therapy At American Diabetes Association
Jul 23, 2025 • Yahoo Finance
Nontuberculous Mycobacteria (NTM) Opportunity Assessment and Forecast to 2033 Featuring Janssen, Novartis, Meiji Seika Pharma, Insmed, Daiichi Sankyo, MannKind, Paratek, Nobelpharma, GSK, Pfizer
Jul 17, 2025 • Research and Markets
MannKind assumed with a Buy at H.C. Wainwright
Jul 16, 2025 • thefly.com
MannKind Corporation(NasdaqGM:MNKD) dropped from Russell Microcap Growth Index
Jun 30, 2025 • MarketScreener
MannKind (MNKD) Presents Pediatric Insulin Trial Data
Jun 23, 2025 • Yahoo Finance
Inhaled Insulin Shown as a Safe and Effective Replacement for Standard-of-Care in Children with Type 1 Diabetes
Jun 22, 2025 • Morningstar.com
Type 1 Diabetes Market Size to Reach USD 9.6 billion by 2035 | Epidemiology, Treatment, Trends & Rising Incidence
Jun 17, 2025 • EIN Presswire
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association’s 85th Scientific Sessions in Chicago, June 20-23
Jun 10, 2025 • BioSpace
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association’s 85th Scientific Sessions in Chicago, June 20-23
Jun 9, 2025 • MannKind
INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29
May 27, 2025 • MannKind
MannKind to Present at Upcoming Investor Conferences
May 13, 2025 • MannKind
MannKind Corporation (MNKD): Among the Best Cancer Stocks to Invest in for Long-Term Gain
May 9, 2025 • Yahoo Finance
MannKind's Q1 Adjusted Earnings, Revenue Increase
May 8, 2025 • MarketScreener
MannKind Non-GAAP EPS of $0.07 beats by $0.01, revenue of $78.35M beats by $2.49M
May 8, 2025 • Seeking Alpha
MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025
May 1, 2025 • MannKind
MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025
May 1, 2025 • BioSpace
Is MannKind Corp. (NASDAQ:MNKD) the Best Biotech Penny Stock to Buy According to Hedge Funds?
Apr 16, 2025 • Insider Monkey
Is MannKind Corp. (NASDAQ:MNKD) the Best Biotech Penny Stock to Buy According to Hedge Funds?
Apr 16, 2025 • Yahoo Finance
Mizuho sets MannKind stock Outperform with $12 target
Apr 9, 2025 • Investing.com
MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options
Apr 7, 2025 • MannKind
Needle Free Diabetes Care Market Analysis and Forecast 2025-2030 - Closed-Loop Systems Becoming More Accessible, User-Friendly, and Effective
Apr 1, 2025 • Research and Markets
Short Acting Insulin Global Market Report 2025: Projected To Reach $14.47 Billion With A CAGR Of 5.6%
Mar 30, 2025 • EIN Presswire
MannKind at Barclays Healthcare Conference: Strategic Growth and Innovation
Mar 12, 2025 • Investing.com
MannKind Corporation Showcases Positive Outcomes of Inhaled Insulin at ATTD 2025 with Anticipated sNDA Filing for Pediatric Use in 2025
Mar 10, 2025 • Nasdaq
MannKind Advances Pediatric Inhaled Insulin Program with 5 Clinical Studies
Mar 10, 2025 • StockTitan
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22
Mar 10, 2025 • BioSpace
MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22
Mar 10, 2025 • GlobeNewswire News Room
MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Feb 26, 2025 • GlobeNewswire
MannKind Corp (MNKD) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...
Feb 26, 2025 • Yahoo Finance
MannKind (MNKD) Files Mixed Shelf
Feb 26, 2025 • StreetInsider.com
Mannkind stock gains amid Q4 report, business update
Feb 26, 2025 • Seeking Alpha
MannKind (MNKD) Files Mixed Shelf
Feb 26, 2025 • StreetInsider.com
MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025
Feb 20, 2025 • BioSpace
MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025
Feb 19, 2025 • GlobeNewswire News Room
Wedbush Initiates Coverage on MannKind (NASDAQ:MNKD) - MarketBeat
Feb 14, 2025 • MarketBeat
SG Americas Securities LLC Has $182,000 Holdings in MannKind Co. (NASDAQ:MNKD) - MarketBeat
Feb 12, 2025 • MarketBeat
MannKind To Present At Oppenheimer Healthcare Life Sciences Conference; Webcast At 11:20 AM ET - Nasdaq
Feb 11, 2025 • Nasdaq
(MNKD) Technical Data - Stock Traders Daily
Feb 11, 2025 • Stock Traders Daily
MannKind (NASDAQ:MNKD) Coverage Initiated by Analysts at Wedbush - Defense World
Feb 11, 2025 • Defense World
MannKind Co. (NASDAQ:MNKD) Shares Sold by Calamos Advisors LLC - MarketBeat
Feb 9, 2025 • MarketBeat